Port Orange
Port Orange
Port Orange, Florida, United States90 results · Page 1 of 4
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study to Compare the Steady-State Bioavailability of Injectable Letrozole SIE and Oral Letrozole in Post-Menopausal Women With Hormone Receptor Positive Early Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Phase 1 | 2026-10-09 | NCT07401381 | |
| A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH) | Digestive System Diseases, fatty liver disease, liver disorder, metabolic dysfunction-associated steatohepatitis, metabolic dysfunction-associated steatotic liver disease | Recruiting | Phase 2 | 2026-10-09 | NCT07288138 | |
| A Study of LY4560736 in Healthy Participants and Participants With Alzheimer's Disease (AD) | Alzheimer disease, Pathological Conditions, Anatomical, Pathological Conditions, Signs and Symptoms, Plaque, Amyloid, amyloidosis, brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathy | Not yet recruiting | Phase 1 | 2026-10-08 | NCT07843459 | |
| A Master Protocol Studying Multiple Amyloid-Targeting Therapies in Healthy Participants and Participants With Alzheimer's Disease | Alzheimer disease, Pathological Conditions, Anatomical, Pathological Conditions, Signs and Symptoms, Plaque, Amyloid, amyloidosis, brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathy | Recruiting | Phase 1 | 2026-10-08 | NCT07787169 | |
| Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities | Body Weight, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, nutritional disorder, obesity disorder, overnutrition | Recruiting | Phase 2 | 2026-10-08 | NCT07752979 | |
| Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH) | Body Weight, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, nutritional disorder, obesity disorder, overnutrition | Recruiting | Phase 3 | 2026-10-08 | NCT07575399 | |
| Study to Assess the Effects of ALN-ANG3 in Adult Participants With Diabetic Kidney Disease | Chronic Disease, Diabetes Complications, Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Nutritional and Metabolic Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Urogenital Diseases, chronic renal failure syndrome, diabetes mellitus, diabetic kidney disease, endocrine system disorder, glucose metabolism disease, kidney disorder, kidney failure, metabolic disease, type 2 diabetes mellitus, urinary system disorder | Recruiting | Phase 2 | 2026-10-08 | NCT07271186 | |
| A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) | Digestive System Diseases, fatty liver disease, liver disorder, metabolic dysfunction-associated steatotic liver disease | Recruiting | Phase 3 | 2026-10-08 | NCT07165028 | |
| Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity | Arterial Occlusive Diseases, Body Weight, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, arteriosclerosis disorder, atherosclerosis, atherosclerotic cardiovascular disease, cardiovascular disorder, nutritional disorder, obesity disorder, overnutrition, vascular disorder | Recruiting | Phase 3 | 2026-10-08 | NCT07037433 | |
| A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) | Arterial Occlusive Diseases, arteriosclerosis disorder, atherosclerosis, cardiovascular disorder, vascular disorder | Active, not recruiting | Phase 3 | 2026-10-08 | NCT06292013 | |
| A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity | Body Weight, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, nutritional disorder, obesity disorder, overnutrition | Recruiting | Phase 3 | 2026-10-07 | NCT07843498 | |
| A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Established Cardiovascular Disease | Body Weight, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, cardiovascular disorder, nutritional disorder, obesity disorder, overnutrition | Recruiting | Phase 3 | 2026-10-07 | NCT07843472 | |
| Prevention of Recurrent C. Difficile Infection Study With AZD5148 Monoclonal Antibody | Bacterial Infections and Mycoses, Clostridium difficile Infections, Clostridium infectious disease, Infections, bacterial infectious disease, gram-positive bacterial infections | Recruiting | Phase 2 | 2026-10-07 | NCT07285213 | |
| Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease | Alzheimer disease, brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathy | Recruiting | Phase 2 | 2026-10-07 | NCT06847321 | |
| A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3) | Alzheimer disease, brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathy | Active, not recruiting | Phase 3 | 2026-10-07 | NCT06653153 | |
| Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D) | Cushing syndrome, Nutritional and Metabolic Diseases, Paraneoplastic Endocrine Syndromes, adrenal gland disorder, adrenal gland hyperfunction, diabetes mellitus, ectopic ACTH secretion syndrome, endocrine system disorder, glucose metabolism disease, metabolic disease, neoplasm, paraneoplastic syndrome, type 2 diabetes mellitus | Recruiting | Phase 2 | 2026-10-06 | NCT07296484 | |
| A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis | MASH With Fibrosis; NASH With Fibrosis | Recruiting | Phase 3 | 2026-10-06 | NCT06215716 | |
| A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease | Alzheimer disease, Cognition Disorders, Cognitive Dysfunction, brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathy | Active, not recruiting | Phase 3 | 2026-10-06 | NCT03887455 | |
| A Study of Modified Release RTN-001 In Patients With Uncontrolled Hypertension | Heart Murmurs, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Systolic Murmurs, cardiovascular disorder, hypertensive disorder, vascular disorder | Recruiting | Phase 2 | 2026-10-02 | NCT07142356 | |
| A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis | Moderately to Severely Active Ulcerative Colitis | Active, not recruiting | Phase 3 | 2026-10-02 | NCT06588855 | |
| Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, invasive breast carcinoma, neoplasm, skin disorder, triple-negative breast carcinoma | Active, not recruiting | Phase 3 | 2026-10-02 | NCT02445391 | |
| LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis | Digestive System Diseases, Fibrosis, Fibrosis, Liver, Pathologic Processes, Pathological Conditions, Signs and Symptoms, cirrhosis of liver, liver disorder | Recruiting | Phase 3 | 2026-10-01 | NCT06632444 | |
| Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial) | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Active, not recruiting | Not applicable | 2026-10-01 | NCT02194738 | |
| Study of Efficacy and Safety of Tonlamarsen in Participants With a Recent Hospitalization and a Concurrent Episode of Acute Severe Hypertension | Hypertensive Crisis, cardiovascular disorder, hypertensive disorder, hypertensive urgency, vascular disorder | Recruiting | Phase 2 | 2026-09-30 | NCT07511361 | |
| A Study of PATAS Using Single Ascending Doses in Healthy Volunteers and Multiple Ascending Doses in Diabetic Subjects | Insulin Resistance, Nutritional and Metabolic Diseases, diabetes mellitus, endocrine system disorder, glucose metabolism disease, hyperinsulinism, metabolic disease, type 2 diabetes mellitus | Recruiting | Phase 1 | 2026-09-29 | NCT07223333 |